"BCG Vaccine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An active immunizing agent and a viable avirulent attenuated strain of Mycobacterium tuberculosis, var. bovis, which confers immunity to mycobacterial infections. It is used also in immunotherapy of neoplasms due to its stimulation of antibodies and non-specific immunity.
| Descriptor ID |
D001500
|
| MeSH Number(s) |
D20.215.894.135.825.100
|
| Concept/Terms |
BCG Vaccine- BCG Vaccine
- Vaccine, BCG
- Bacillus Calmette Guerin Vaccine
- Calmette Guerin Bacillus Vaccine
- Calmette's Vaccine
- Calmette Vaccine
- Calmettes Vaccine
- Vaccine, Calmette's
|
Below are MeSH descriptors whose meaning is more general than "BCG Vaccine".
Below are MeSH descriptors whose meaning is more specific than "BCG Vaccine".
This graph shows the total number of publications written about "BCG Vaccine" by people in this website by year, and whether "BCG Vaccine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1998 | 1 | 1 | 2 |
| 2003 | 2 | 0 | 2 |
| 2004 | 3 | 0 | 3 |
| 2005 | 2 | 3 | 5 |
| 2006 | 0 | 1 | 1 |
| 2007 | 2 | 0 | 2 |
| 2008 | 3 | 3 | 6 |
| 2010 | 0 | 3 | 3 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 3 | 1 | 4 |
| 2014 | 1 | 1 | 2 |
| 2016 | 1 | 1 | 2 |
| 2017 | 0 | 1 | 1 |
| 2018 | 2 | 1 | 3 |
| 2019 | 3 | 0 | 3 |
| 2020 | 3 | 1 | 4 |
| 2021 | 3 | 7 | 10 |
| 2022 | 1 | 3 | 4 |
| 2023 | 0 | 3 | 3 |
| 2024 | 6 | 0 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "BCG Vaccine" by people in Profiles.
-
Effectiveness of the primary Bacillus Calmette-Gu?rin vaccine against the risk of Mycobacterium tuberculosis infection and tuberculosis disease: a meta-analysis of individual participant data. Lancet Microbe. 2025 Feb; 6(2):100961.
-
Oncologic Outcomes of Sequential Intravesical Gemcitabine and Docetaxel Compared with Bacillus Calmette-Gu?rin in Patients with Bacillus Calmette-Gu?rin-Unresponsive Non-Muscle Invasive Bladder Cancer. Eur Urol Oncol. 2025 Apr; 8(2):469-476.
-
Unmet Need in Non-muscle-invasive Bladder Cancer Failing Bacillus Calmette-Gu?rin Therapy: A Systematic Review and Cost-effectiveness Analyses from the International Bladder Cancer Group. Eur Urol Oncol. 2025 Feb; 8(1):216-229.
-
Minimal Residual Disease Detection with Urine-derived DNA Is Prognostic for Recurrence-free Survival in Bacillus Calmette-Gu?rin-unresponsive Non-muscle-invasive Bladder Cancer Treated with Nadofaragene Firadenovec. Eur Urol Oncol. 2025 Apr; 8(2):425-434.
-
Predicting Response to Intravesical Bacillus Calmette-Gu?rin in High-Risk Nonmuscle-Invasive Bladder Cancer Using an Artificial Intelligence-Powered Pathology Assay: Development and Validation in an International 12-Center Cohort. J Urol. 2025 Feb; 213(2):192-204.
-
Long-term outcomes of bladder-sparing therapy vs radical cystectomy in BCG-unresponsive non-muscle-invasive bladder cancer. BJU Int. 2025 Feb; 135(2):260-268.
-
Bladder-sparing Therapy for Bacillus Calmette-Gu?rin-unresponsive Non-muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection. Eur Urol. 2024 Dec; 86(6):516-527.
-
Reply: Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Gu?rin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial. J Urol. 2024 Oct; 212(4):625.
-
Challenging the Paradigm of "BCG-unresponsive" Bladder Cancer: Does Additional Bacillus Calmette-Gu?rin Have an Effect? Eur Urol. 2024 Oct; 86(4):366-368.
-
Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial. Nat Med. 2024 Aug; 30(8):2216-2223.